Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Genomics: MDS pathology & treatment

Rafael Bejar • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center, San Diego, CA, discusses the importance of genomics in the treatment, prognostics and diagnostics of myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Rafael Bejar

CHIP and implications for myeloproliferative neoplasms
Rafael Bejar • 10 Nov 2022
1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
1:45
The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar • 26 Aug 2022

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals